Substitute for form 1449A/PTO				Co	mplete if Known	
				Application Number		33.
INFO	RMATION D	ISC	LOSURE	Filing Date	On Even Date Herewith	5.6
STATEMENT BY APPLICANT				First Named Inventor	Daniel G. CHAIN	25
017.		- \	LIOAITI	Group Art Unit	1632	200
	(use as many sheets	as n	ecessary)	Examiner Name		<u> </u>
Sheet	1	of	3	Attorney Docket Number	CHAIN=1C	

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	U.S. Patent Number	Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	AA	5,441,870		Seubert et al	08-15-1995			
	AB	5,688,651		Solomon et al	11-18-1997			
	AC	5,721,130		Seubert et al	02-24-1998			
					+			
			1					
					+			

	FOREIGN PATENT DOCUMENTS							
			Foreign Patent Nu	mber	Name of Patentee or Applicant	Date of Publication	Pages, Columns, Lines,	
Examiner Initials*	Cite No.1	Office ³	Number	Kind Code ⁵ (if known)	of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ⁶
	AD	EP	0 683 234	A1	Takada	11-22-1995		
	AE	wo	89/01975	A1	Cattaneo	03-09-1989		
	AF	wo	96/18900	A1	Solomon	06-20-1996		
	•							
							-	

Examiner	Date	
Signature	Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute t	for form 1449A/PTO			Complete if Known		
Cubolituto				Application Number		
INFO	RMATION D	ISC	LOSURE	Filing Date	On Even Date Herewith	
STAT	EMENT BY	ΔP	PLICANT	First Named Inventor	Daniel G. CHAIN	
• • • • • • • • • • • • • • • • • • • •		<i>,</i>	. 2.07	Group Art Unit	1632	
	(use as many sheet	s as n	ecessary)	Examiner Name		
Sheet	2	of	3	Attorney Docket Number	CHAIN=1C	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	AG	GRAVINA et al, "Amyloid β Protein (Aβ) in Alzheimer's Disease Brain: Biochemical and Immunocytochemical Analysis with Antibodies Specific for Forms Ending at Aβ40 or Aβ42(43)", <u>J Biol Chem</u> 270(13):7013-7016 (1995)	
	АН	HANAN et al, "Inhibitory effect of monoclonal antibodies on Alzheimer's Beta-amyloid peptide aggregation", Int J Exp Clin Invest 3:130-133 (1996)	
	Al	HARRINGTON et al, "Characterisation of an epitope specific to the neuron-specific isoform of human enolase recognized by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β/A4-protein", Biochim Biophys Acta 1158:120-127 (1993)	
	AJ	HIGGINS et al, "Transgenic Mouse Brain Histophathology Resembles Early Alzheimer's Disease", <u>Ann Neurol</u> 35:598-607 (1994)	
	AK	IWATSUBO et al, "Visualization of Aβ42(43) and Aβ40 in Senile Plaques with End-Specific Aβ Monoclonals: Evidence that an Initially Deposited species Is Aβ42(43) Neuron 13:45-53 (1994)	
	AL	IWATSUBO et al, "Amyloid β Protein (Aβ) Depostiion: Aβ42(43) Precedes Aβ40 in Down Syndrome", <u>Ann Neurol</u> 37:294-299 (1995)	
	AM	KÖNIG et al, "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl- Terminus of the βA4 Peptide", <u>Ann NY Acad Sci</u> 777:345-355 (1996)	
	AN	MANN et al, "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype", Neurosci Letters 196(1-2):105-108 (1995)	
	AO	MANN et al, Predominant Deposition of Amyloid-β ₄₂₍₄₃₎ in Plaques in Cases of Alzheimer's Disease and Hereditary Cerebral Hemorrhage Associated with Mutations in the Amyloid Precursor Protein Gene", <u>Am J Pathol</u> 148(4):1257-1265 (1996	
	AP	MANN et al, "Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta 42(43)", <u>Ann Neurol</u> 40(2):149-156 (1996)	
	AQ	MURPHY et al, "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders", <u>Am J Pathol</u> 144(5):1082-1088 (1994)	
	AR	NAKAMURA et al, " Carboxyl end-specific monoclonal antibodies to amyloid beta protein (A beta) subtypes (A beta 40 and A beta 42(43)) differentiate A beta in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys", Neurosci Letters 201(2):151-154 (1996)	

Examiner Signature	Date Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Substitute t	for form 1449A/PTO			Complete if Known		
				Application Number		
INFO	RMATION DIS	SC	LOSURE	Filing Date	On even date herewith	
STAT	EMENT BY A	ΔPI	PLICANT	First Named Inventor	Daniel G. CHAIN	
• . ,		` '	LIO/(IV)	Group Art Unit	1632	
	(use as many sheets	as ne	ecessary)	Examiner Name		
Sheet	3	of	3	Attorney Docket Number	CHAIN=1C	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	AS	SAIDO et al, "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain", <u>J Biol Chem</u> 268(33):25239-25243 (1993)	
	AY	SOLOMON et al, "Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer Beta-amyloid peptide", Proc Nat Acad Sci, USA 93:452-455 (1996)	
	AU	SOLOMON et al, "Disaggregation of Alzheimer Beta-amyloid by site-directed mAb", <u>Proc Nat Acad Sci USA</u> 94:4109-4112 (1996)	
	AV	SUZUKI et al, "High Tissue Content of Soluble β1-40 is Linked to Cerebral Amyloid Angiopathy", Am J Pathol 145(2):452-460 (1994)	
	AW	TAMAOKA et al, "Amyloid β protein 1-42/43 (Aβ 1-42/43) in cerebellar diffuse plaques: enzyme-linked immunosorbent assay and immunocytochemical study", <u>Brain Res</u> 679:151-156 (1995)	
	AX	TSUZUKI et al, "Amyloid beta protein in rat soleus muscle in chloroquine-induced myopathy using end-specific antibodies for A beta 40 and A beta 42: immunohistochemical evidence for amyloid beta protein", Neurosci Letters 202(1-2):77-80 (1995)	
	AY	TURNER et al, "Mayloids β ₄₀ and β ₄₂ Are Generated Intracellularly in Cultured Human Neurons and Their Secretion Increases with Maturation", <u>J Biol Chem</u> 271(15):8966-8970 (1996)	
	AZ	YANAGISAWA et al, "Fractionation of Amyloid β-Protein (Aβ) in Alzheimer's Disease and Down's Syndrome Brains: Presence of Membrane-Bound Aβ", <u>Ann NY Acad Sci</u> 786:184-194 (1996)	
	<u> </u>		

Examiner	Date	1
Signature	Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.